Management strategies for locally advanced prostate cancer

Drugs and Aging

Volumn 23, Issue 2, 2006, Pages 119-129

  Jani, Ashesh B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; CARBOPLATIN; CYPROTERONE ACETATE; CYTOSINE DEAMINASE; DOCETAXEL; DOXORUBICIN; E1A PROTEIN; ESTRAMUSTINE; FLUOROURACIL; FLUTAMIDE; GANCICLOVIR; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SULINDAC SULFONE; THYMIDINE KINASE; VALACICLOVIR;

ABDOMINAL RADIOGRAPHY; ADJUVANT THERAPY; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; LABORATORY TEST; LIVER TOXICITY; METASTASIS; MORBIDITY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; PELVIS LYMPH NODE; PELVIS RADIOGRAPHY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; RADIATION DOSE; REVIEW; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT PLANNING; URINE RETENTION; UROGENITAL TRACT DISEASE; VIRAL GENE THERAPY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOADJUVANT THERAPY; PRACTICE GUIDELINES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33644969285     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623020-00003     Document Type: Review

References (64)

1. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003; 361 (9362): 1048-53
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361 (9360): 859-64
3. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet 2003; 361 (9363): 1122-8
4. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4 (4): 233-41
5. Jemal A, Murray T, Ward W, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55 (1): 10-30
6. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8 (2): 126-31
7. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127 (5): 928-34
8. AJCC (American Joint Committee on Cancer). Cancer staging manual. In: Greene FL, Page DL, Fleming ID, et al., editors. 6th ed. New York: Springer-Verlag, 2002: 310
9. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124 (7): 995-1000
10. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58 (6): 843-8
11. Levran Z, Gonzalez JA, Diokno AC, et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75 (6): 778-81
12. Gleave ME, Coupland D, Drachenberg D, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47 (5): 708-12
13. Tsuda K, Yu KK, Coakley FV, et al. Detection of extracapsular extension of prostate cancer: role of fat suppression endorectal MRI. J Comput Assist Tomogr 1999; 23 (1): 74-8
14. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54 (6): 1058-63
15. Sanz G, Rioja J, Zudaire JJ, et al. PET and prostate cancer. World J Urol 2004; 22 (5): 351-2
16. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348 (25): 2491-9
17. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355 (9214): 1491-8
18. Fusi A, Procopio G, Della Torre S, et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004; 90 (6): 535-46
19. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 2004; 171 (2 Pt 1): 668-71
20. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95 (6): 751-6
21. van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. 1: staging, natural history, and results of radical surgery. World J Urol 2000; 18 (3): 194-203
22. Schulam PG, Link RE. Laparoscopic radical prostatectomy. World J Urol 2000; 18 (4): 278-82
23. Akakura K, Isaka S, Akimoto S, et al. Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999; 54 (2): 313-8
24. Blasko JC, Ragde H, Grimm PD, et al. Prostate brachytherapy: importance of technique. J Clin Oncol 1996; 14 (6): 1965-7
25. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001; 49 (1): 61-9
26. Hanks GE, Krall JM, Hanlon AL, et al. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 1994; 28 (1): 39-45
27. Krengli M, Liebsch NJ, Hug EB, et al. Review of current protocols for proton therapy in USA. Tumori 1998; 84 (2): 209-16
28. Forman JD, Yudelev M, Bolton S, et al. Fast neutron irradiation for prostate cancer. Cancer Metastasis Rev 2002; 21 (2): 131-5
29. Bagshaw MA, Kaplan ID, Cox RC. Prostate cancer. Radiation therapy for localized disease. Cancer 1993; 71 (3 Suppl.): 939-52
30. Zietman AL, Coen JJ, Dallow KC, et al. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995; 32 (2): 287-92
31. Huggins C. Endocrine-induced regression of cancers. Science 1967; 156 (778): 1050-4
32. Jani AB. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5 (12): 2469-77
33. Jani A, Vogelzang NJ. Re: Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2001; 166 (2): 631-2
34. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50 (5): 1243-52
35. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37 (2): 247-52
36. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49 (4): 937-46
37. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360 (9327): 103-6
38. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21 (21): 3972-8
39. Roach 3rd M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21 (10): 1904-11
40. Jani AB, Kao J, Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer 2003; 98 (11): 2351-61
41. Jani AB, Su A, Milano MT. Intensity modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 2006; 67 (1): 147-51
42. Jani AB, Roeske JC, Rash C. Intensity-modulated radiation therapy for prostate cancer. Clin Prostate Cancer 2003; 2 (2): 98-105
43. Radiation Therapy Oncology Group. A phase III trial to evaluate the duration of neoadjuvant total androgen suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer (RTOG 99-10) [online]. Available from URL: http://www.rtog.org [Accessed 2006 Feb 6]
44. Jani AB, Gratzle J, Muresan E, et al. Analysis of acute toxicity with use of transabdominal ultrasonography for prostate positioning during intensity-modulated radiotherapy. Urology 2005; 65 (3): 504-8
45. Jani AB, Gratzle J, Muresan E, et al. Impact on late toxicity of using transabdominal ultrasound for prostate cancer patients treated with intensity modulated radiotherapy. Technol Cancer Res Treat 2005; 4 (1): 115-20
46. Jani AB. Organ motion and IMRT in prostate cancer therapy. Cancer J 2003; 9 (4): 244-6
47. Vicini FA, Vargas C, Edmundson G, et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol 2003; 13 (2): 98-108
48. Klein EA, Kupelian PA, Dreicer R, et al. Locally advanced prostate cancer. Curr Treat Options Oncol 2001; 2 (5): 403-11
49. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol March 2000; 18 (5): 1050-7
50. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171 (2 Pt 1): 709-13
51. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61 (4): 774-80
52. Zelefsky MJ, Kelly WK, Scher HI, et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 2000; 18 (9): 1936-41
53. Cancer and Leukemia Group B. Phase II study of neoadjuvant paclitaxel, estramustine, carboplatin, and androgen ablation followed by radiotherapy in patients with poor-prognosis locally advanced prostate cancer (CALGB 99811) [online]. Available from URL: http://www.calgb.org [Accessed 2006 Feb 6]
54. Radiation Therapy Oncology Group. A phase III protocol of androgen suppression (AS) and radiation therapy (RT) vs AS and RT followed by chemotherapy with paclitaxel, estramustine, and exisuland (TEE) for localized, high-risk, prostate cancer (RTOG P-0014) [online]. Available from URL: http://www.rtog.org [Accessed 2006 Feb 6]
55. Radiation Therapy Oncology Group. A phase III randomized study of patients with high-risk, hormone-naïve prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy (RTOG P-0014) [online]. Available from URL: http://www.r-tog.org [Accessed 2006 Feb 6]
56. Chhikara M, Huang H, Vlachaki MT, et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001; 3 (4): 536-42
57. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61 (14): 5453-60
58. Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9 (9): 1323-33
59. Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys 2000; 48 (5): 1507-12
60. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10 (7): 1239-49
61. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61 (20): 7464-72
62. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62 (17): 4968-76
63. Teh BS, Aguilar-Cordova E, Kernen K, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer: a preliminary report. Int J Radiat Oncol Biol Phys 2001; 51 (3): 605-13
64. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63 (21): 7497-506